BIELLO, FEDERICA
 Distribuzione geografica
Continente #
EU - Europa 336
Totale 336
Nazione #
IT - Italia 336
Totale 336
Città #
Genova 166
Rapallo 99
Genoa 64
Bordighera 7
Totale 336
Nome #
Circulating tumor DNA reflects tumor metabolism rather than tumor burden in chemotherapy-naive patients with advanced non–small cell lung cancer:18F-FDG PET/CT study, file e268c4c8-c8c7-a6b7-e053-3a05fe0adea1 67
Circulating cell-free DNA and circulating tumor cells as prognostic and predictive biomarkers in advanced non-small cell lung cancer patients treated with first-line chemotherapy, file e268c4cc-cf27-a6b7-e053-3a05fe0adea1 58
Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy, file e268c4cc-f3f7-a6b7-e053-3a05fe0adea1 56
The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients, file e268c4cc-e1c1-a6b7-e053-3a05fe0adea1 55
Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy, file e268c4cc-e011-a6b7-e053-3a05fe0adea1 43
Resistin is associated with overall survival in non-small cell lung cancer patients during nivolumab treatment, file e268c4cb-be83-a6b7-e053-3a05fe0adea1 21
Serum levels of VCAM-1 are associated with survival in patients treated with nivolumab for NSCLC, file e268c4cd-b5d3-a6b7-e053-3a05fe0adea1 12
Afatinib for the treatment of non-small cell lung cancer, file e268c4cc-dd48-a6b7-e053-3a05fe0adea1 3
Afatinib and Erlotinib in the treatment of squamous-cell lung cancer, file e268c4cc-e924-a6b7-e053-3a05fe0adea1 3
Uncommon EGFR Exon 19 Mutations Confer Gefitinib Resistance in Advanced Lung Adenocarcinoma, file e268c4ca-2cb2-a6b7-e053-3a05fe0adea1 2
Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy, file e268c4ca-7907-a6b7-e053-3a05fe0adea1 2
Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients, file e268c4ca-b88d-a6b7-e053-3a05fe0adea1 2
Nivolumab treatment in advanced lung cancer patient with chronic active hepatitis C and systemic lupus erythematosus., file e268c4ca-464d-a6b7-e053-3a05fe0adea1 1
Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study, file e268c4ca-9f33-a6b7-e053-3a05fe0adea1 1
Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer, file e268c4ca-d189-a6b7-e053-3a05fe0adea1 1
Vinflunine for the treatment of non-small cell lung cancer, file e268c4cc-cd62-a6b7-e053-3a05fe0adea1 1
CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine, file e268c4cc-d50e-a6b7-e053-3a05fe0adea1 1
The evolving role of pemetrexed disodium for the treatment of non-small cell lung cancer, file e268c4cc-e01e-a6b7-e053-3a05fe0adea1 1
New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer, file e268c4cc-f3f5-a6b7-e053-3a05fe0adea1 1
Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer, file e268c4cc-f3f9-a6b7-e053-3a05fe0adea1 1
Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer, file e268c4cc-f3fb-a6b7-e053-3a05fe0adea1 1
Comparison between 18F-FDG-PET- and CT-based criteria in non-small cell lung cancer (NSCLC) patients treated with Nivolumab, file e268c4cd-09dc-a6b7-e053-3a05fe0adea1 1
Current state of the art and future perspectives with immunotherapy in the management of small cell lung cancer, file e268c4ce-62ef-a6b7-e053-3a05fe0adea1 1
Novel approaches for the treatment of unresectable malignant pleural mesothelioma: A focus on immunotherapy and target therapy (Review), file e268c4ce-e0a3-a6b7-e053-3a05fe0adea1 1
Totale 336
Categoria #
all - tutte 1.152
article - articoli 1.152
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.304


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20205 1 0 0 0 0 2 0 0 1 1 0 0
2020/202170 0 4 7 9 0 2 1 5 18 14 2 8
2021/202297 9 1 1 4 6 7 5 4 7 9 35 9
2022/2023109 1 3 27 21 5 28 4 9 1 3 7 0
2023/202455 0 1 4 4 14 3 13 9 2 2 3 0
Totale 336